These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 18421299)
1. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Zhou XD; Agazie YM Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299 [TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. Zhou X; Agazie YM J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604 [TBL] [Abstract][Full Text] [Related]
3. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Matalkah F; Martin E; Zhao H; Agazie YM Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. Zhao H; Agazie YM BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600 [TBL] [Abstract][Full Text] [Related]
5. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913 [TBL] [Abstract][Full Text] [Related]
6. SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1. Li S; Wang L; Zhao Q; Liu Y; He L; Xu Q; Sun X; Teng L; Cheng H; Ke Y J Biol Chem; 2014 Dec; 289(49):34152-60. PubMed ID: 25331952 [TBL] [Abstract][Full Text] [Related]
7. Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling. Wang Q; Pan W; Wang S; Pan C; Ning H; Huang S; Chiu SH; Chen JL J Virol; 2021 Feb; 95(6):. PubMed ID: 33361428 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types. Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Lo HW; Hsu SC; Xia W; Cao X; Shih JY; Wei Y; Abbruzzese JL; Hortobagyi GN; Hung MC Cancer Res; 2007 Oct; 67(19):9066-76. PubMed ID: 17909010 [TBL] [Abstract][Full Text] [Related]
11. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. Li Q; Mattingly RR Neoplasia; 2008 Dec; 10(12):1444-58. PubMed ID: 19048123 [TBL] [Abstract][Full Text] [Related]
12. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). Hartman Z; Geldenhuys WJ; Agazie YM J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694 [TBL] [Abstract][Full Text] [Related]
13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368 [TBL] [Abstract][Full Text] [Related]
14. Taiwan cobra cardiotoxin III suppresses EGF/EGFR-mediated epithelial-to-mesenchymal transition and invasion of human breast cancer MDA-MB-231 cells. Tsai PC; Fu YS; Chang LS; Lin SR Toxicon; 2016 Mar; 111():108-20. PubMed ID: 26774845 [TBL] [Abstract][Full Text] [Related]
15. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Uttamsingh S; Bao X; Nguyen KT; Bhanot M; Gong J; Chan JL; Liu F; Chu TT; Wang LH Oncogene; 2008 Apr; 27(18):2626-34. PubMed ID: 17982486 [TBL] [Abstract][Full Text] [Related]
16. Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Wang J; Kuiatse I; Lee AV; Pan J; Giuliano A; Cui X Mol Cancer Res; 2010 Feb; 8(2):266-77. PubMed ID: 20145041 [TBL] [Abstract][Full Text] [Related]
17. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells. McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542 [TBL] [Abstract][Full Text] [Related]
18. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Zhou X; Coad J; Ducatman B; Agazie YM Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929 [TBL] [Abstract][Full Text] [Related]
19. Gamma tocotrienol targets tyrosine phosphatase SHP2 in mammospheres resulting in cell death through RAS/ERK pathway. Gu W; Prasadam I; Yu M; Zhang F; Ling P; Xiao Y; Yu C BMC Cancer; 2015 Aug; 15():609. PubMed ID: 26315028 [TBL] [Abstract][Full Text] [Related]
20. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]